{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T04:15:27Z","timestamp":1683173727519},"reference-count":35,"publisher":"SLACK, Inc.","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychosoc Nurs Ment Health Serv"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>\n            As the opioid crisis continues to worsen in the United States, nurses must take on a central role of intervention, which includes use of the opioid agonist medication, buprenorphine. The current article addresses the need to understand opioid use disorder as a chronic condition and increase access to treatment with pharmacotherapies, particularly buprenorphine, in outpatient settings. The pharmacological activity of buprenorphine is discussed, as well as the reasons for its underutilization, specifically stigma. Nurses can be frontline leaders in the fight against the opioid crisis by addressing stigma and increasing access to the life-saving medication, buprenorphine. [\n            <jats:italic>Journal of Psychosocial Nursing and Mental Health Services, 56<\/jats:italic>\n            (11), 9\u201312.]\n          <\/jats:p>","DOI":"10.3928\/02793695-20181012-02","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T19:52:09Z","timestamp":1541101929000},"page":"9-12","source":"Crossref","is-referenced-by-count":0,"title":["Use of Buprenorphine to Treat Opioid Use Disorder"],"prefix":"10.3928","volume":"56","author":[{"given":"Lydia Anne M.","family":"Bartholow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Pope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.2013.74.258"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2005.02.007"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2014.991469"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12652"},{"issue":"1","key":"e_1_3_1_6_1","first-page":"3019","article-title":"Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians","volume":"15","author":"DeFlavio J.R.","year":"2015","unstructured":"DeFlavio J.R., Rolin S.A., Nordstrom B.R., Kazal L.A.. (2015). Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural & Remote Health, 15(1), 3019.","journal-title":"Rural & Remote Health"},{"key":"e_1_3_1_7_1","unstructured":"Drug Enforcement Administration. (2013 July). Buprenorphine . Retrieved from https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/buprenorphine.pdf"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5302"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2017.1385633"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.04.005"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1595"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302664"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S85951"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.2014.75.476"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.05.025"},{"issue":"3","key":"e_1_3_1_17_1","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"3","author":"Mattick R.P.","year":"2004","unstructured":"Mattick R.P., Kimber J., Breen C., Davoli M. (2004). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 3(3), CD002207.","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_3_1_18_1","unstructured":"National Institute on Drug Abuse. (2016 November). Effective treatments for opioid addiction . Retrieved from https:\/\/www.drugabuse.gov\/publications\/effective-treatments-opioid-addiction\/effective-treatments-opioid-addiction"},{"key":"e_1_3_1_19_1","unstructured":"National Institutes of Health. (1997). Effective medical treatment of opiate addiction . Retrieved from https:\/\/consensus.nih.gov\/1997\/1998treatopiateaddiction108html.htm"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2008.06.006"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm655051e1"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.301049"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.2421"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2017.19.3\/msoyka"},{"key":"e_1_3_1_25_1","unstructured":"Substance Abuse and Mental Health Services Administration. (2015 October 27). Substance use disorders . Retrieved from https:\/\/www.samhsa.gov\/disorders\/substance-use"},{"key":"e_1_3_1_26_1","unstructured":"Substance Abuse and Mental Health Services Administration. (2018a). Buprenorphine waiver management . Retrieved from https:\/\/www.samhsa.gov\/programs-campaigns\/medication-assisted-treatment\/training-materials-resources\/buprenorphine-waiver"},{"key":"e_1_3_1_27_1","unstructured":"Substance Abuse and Mental Health Services Administration. (2018b). Legislation regulations and guidelines . Retrieved from https:\/\/www.samhsa.gov\/programs-campaigns\/medication-assisted-treatment\/legislation-regulations-guidelines"},{"key":"e_1_3_1_28_1","unstructured":"Substance Abuse and Mental Health Services Administration. (2018c). Treatment Improvement Protocol 63: Medications for opioid use disorder . Retrieved from https:\/\/store.samhsa.gov\/shin\/content\/SMA18-5063FULLDOC\/SMA18-5063FULLDOC.pdf"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.10.002"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.02.018"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1402780"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000275"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2017.1363238"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.08.589"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2015.1059714"},{"key":"e_1_3_1_36_1","unstructured":"World Health Organization. (2017). The selection and use of essential medicines: Report of the WHO Expert Committee 2017 (including the 20th WHO model list of essential medicines and the 6th WHO model list of essential medicines for children) . Retrieved from http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/259481\/9789241210157-eng.pdf;jsessionid=F345DB1B3B4BFF14138C3D2B9F6C667F?sequence=1"}],"container-title":["Journal of Psychosocial Nursing and Mental Health Services"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/doiresolver?doi=10.3928\/02793695-20181012-02","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T03:24:06Z","timestamp":1683084246000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/02793695-20181012-02"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.3928\/02793695-20181012-02"],"URL":"https:\/\/doi.org\/10.3928\/02793695-20181012-02","relation":{},"ISSN":["0279-3695","1938-2413"],"issn-type":[{"value":"0279-3695","type":"print"},{"value":"1938-2413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}